ASAP3 activates the NF-κB signaling pathway to promote the progression of esophageal squamous cell carcinoma Authors: Jingyu Liu, Chenlu Dai, Li Liu, Min Ji, Gulirena Mijiti, Mengjie Zhuang, Sensen Zhu, Ming Cheng, Xuanming Liu, Linlin Zhang, Wei Zhang, Liping Su, Hongwei Pu Published: 2026 ABSTRACT BackgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide. Despite advances in diagnosis and treatment, the lack of effective therapeutic targets continues to limit improvements in patient outcomes. ASAP3 has been implicated in tumor progression; however, its role and underlying mechanisms in ESCC remain unclear.MethodsParaffin-embedded ESCC tissues were analyzed by immunohistochemistry to evaluate the expression of ASAP3, NEMO, p65, phosphorylated p65 (p-p65), and MMP9 and their associations with clinicopathological parameters. In vitro, ASAP3 was silenced to assess its effects on ESCC cell proliferation, migration, and invasion and to explore the underlying mechanisms. In vivo, the role of ASAP3 in ESCC growth was validated using a mouse xenograft model, with tumor size and volume measured and changes in ASAP3, NEMO, p65, and p-p65 expression further analyzed.ResultsClinicopathological analysis showed that elevated ASAP3, NEMO, p65, p-p65, and MMP9 expression in ESCC tissues was associated with poor prognosis. In vitro, ASAP3 knockdown inhibited the proliferation, migration, and invasion of KYSE450 cells. In vivo, ASAP3 silencing suppressed xenograft tumor growth and reduced tumor proliferative activity. Mechanistically, ASAP3 downregulation decreased NEMO expression and p65 phosphorylation, thereby suppressing ESCC cell proliferation, migration, and invasion.ConclusionsCollectively, ASAP3 may promote ESCC progression by interacting with NEMO and activating NF-κB signaling. These findings suggest that ASAP3 functions as an oncogenic driver and may serve as a potential biomarker in ESCC.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-026-05368-4. Introduction Esophageal squamous cell carcinoma (ESCC), the major histological subtype of esophageal cancer, is a common malignancy and one of the leading causes of cancer-related death worldwide [1, 2]. It is also highly prevalent in China. ESCC is highly aggressive and is often associated with late diagnosis, metastasis, recurrence, and treatment resistance [3, 4]. Despite advances in diagnostic and therapeutic strategies, the 5-year overall survival rate remains poor, at only 15–20%. Early detection and timely treatment can substantially improve ESCC survival [2, 5]. Therefore, identifying novel biomarkers and clarifying the underlying pathogenic mechanisms are essential for improving the diagnosis and treatment of ESCC. ASAP3, also known as ACAP4, is a GTPase-activating protein (GAP) for ADP-ribosylation factor 6 (ARF6) and contains BAR, PH, ankyrin repeat, and GAP domains [6, 7]. ASAP3 is expressed at very low levels-or is nearly undetectable-in normal epithelial cells, but it is upregulated in a range of human cancers, including lung cancer [8, 9], colorectal cancer [10, 11], glioma [12], and breast cancer [13]. Okabe and colleagues initially identified it as a development and differentiation–enhancing factor (termed DDEFL1) and showed that it promotes proliferation of hepatocellular carcinoma cells [14]. However, the role of ASAP3 in ESCC remains unclear. In this study, we aimed to evaluate the potential biological functions of ASAP3 in ESCC progression. The transcription factor nuclear factor-κB (NF-κB) plays an important role in various cancers. The NF-κB family consists of five members: RelA/p65, RelB, c-Rel, NF-κB1/p50, and NF-κB2/p52. NF-κB often functions as an oncogenic regulator and plays a complex role in tumor development and progression [15]. The predominant form of NF-κB is a p50/p65 heterodimer. The p65 subunit contains a transcriptional activation domain and regulates key cancer-related processes, including cell survival, invasion, proliferation, metastasis, angiogenesis, and chemoresistance [16]. NF-κB is activated through two distinct pathways: the canonical and non-canonical pathways. In the canonical pathway, various stimuli activate the IκB kinase (IKK) complex, which consists of the catalytic subunits IKKα and IKKβ and the regulatory subunit NF-κB essential modulator (NEMO/IKKγ), leading to activation of the RelA/p50 dimer [17]. IKK then phosphorylates IκB, triggering its ubiquitin-dependent degradation and allowing NF-κB to translocate into the nucleus, where it regulates the expression of downstream target genes [18]. TRAF6 cooperates with the E2 ubiquitin-conjugating enzymes UBC13 and UEV1A to catalyze K63-linked polyubiquitination of TRAF6 and NEMO, the regulatory subunit of the IKK complex, thereby activating the IKK/NF-κB signaling pathway [19]. Tian et al. [10] found that in colorectal cancer, ASAP3 may regulate NF-κB by binding to NEMO. In this study, we demonstrated that ASAP3 promotes ESCC cell proliferation, migration, and invasion in vitro. Mechanistically, ASAP3 may activate NF-κB signaling by interacting with NEMO, thereby enhancing ESCC progression. In vivo, ASAP3 silencing inhibited tumor growth and malignant progression. Materials and methods The patient samples Human ESCC tissue samples were obtained from patients who underwent surgical resection at the First Affiliated Hospital of Xinjiang Medical University, China, between 2013 and 2018. Eligible patients had pathologically confirmed ESCC, no history of chemotherapy or radiotherapy, and complete clinicopathological data. Patients with metastases from other primary tumors or inconclusive immunohistochemical results due to tissue detachment were excluded. Criteria for evaluating IHC results The immunoreactions were evaluated independently by two pathologists. IHC scoring method was as follows: Five high-power fields (200×) were randomly selected from each section and evaluated using a double-blind method. The score was calculated based on staining intensity and the percentage of the area occupied by positive cells. Staining intensity was classified as no staining (colorless, scored as 0), weak staining (light yellow, scored as 1), moderate staining (light brown, scored as 2), and strong staining (dark brown, scored as 3). The percentage of positive cells was scored as follows: 0 was scored as 0, 1%–30% was scored as 1, > 30%–60% was scored as 2, and > 60%–90% was scored as 3.The staining results were recorded according to the staining index: 0–3 points were considered negative, and 4–9 points were considered positive. The staining index was calculated as follows: staining index = percentage of positive cells × staining intensity. Cell culture Human ESCC cell lines KYSE30, KYSE150, and KYSE450 were obtained from Servicebio (Wuhan, China). The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin and maintained at 37 °C in a humidified incubator with 5% CO₂. Cell transfection KYSE450 cells in good growth condition were assigned to five groups: CON, NC, shASAP3#1, shASAP3#2, and shASAP3#3. At approximately 50% confluence, each well was supplemented with 1 mL of complete medium containing 40 µL poly(L-lysine) and 2.5 µL of ASAP3-targeting lentivirus, corresponding to shASAP3#1, shASAP3#2, or shASAP3#3. After 16 h of transduction, the medium was replaced with complete medium containing puromycin (6 mg/mL) for selection and refreshed every other day. When cell confluence reached approximately 80%, total cellular protein was extracted to evaluate knockdown efficiency. The shRNA construct with the highest knockdown efficiency was selected for subsequent experiments. Thereafter, cells were divided into three groups: CON, NC, and shASAP3#3. The shRNA sequences are listed in Supplementary Table S1. Cell counting Kit-8 (CCK-8) According to the manufacturer’s instructions, cells were seeded in 96-well plates at a density of 0.5 × 10³ cells/well in 100 µL of culture medium. Cells were incubated at 37 °C in a humidified atmosphere with 5% CO₂ for 0, 24, 48, and 72 h. At each time point, 10 µL of CCK-8 reagent was added to each well, followed by incubation for 2 h at room temperature. Absorbance was then measured at 450 nm using a microplate reader (Thermo Fisher Scientific). Colony formation assay Cells in optimal growth condition were selected from each group, diluted to a final density of 1 × 10³ cells/well, and seeded into 6-well plates. The cells were incubated at 37 °C in a humidified atmosphere with 5% CO₂ for 14 days. Colonies were then fixed with 4% paraformaldehyde for 30 min, stained with 0.01% crystal violet, and examined under a microscope. Flow cytometry Apoptosis was assessed by flow cytometry. Briefly, cells in good growth condition were selected from each group, seeded into 6-well plates at a density of 5 × 10⁵ cells/well, and incubated for 24 h at 37 °C in a humidified atmosphere with 5% CO₂. According to the manufacturer’s protocol, cells were then harvested, stained with an Annexin V–7-AAD apoptosis detection kit (BD Biosciences, USA), and analyzed by flow cytometry. Wound healing assay For each group, cells in the logarithmic growth phase were seeded into 6-well plates at a density of 5 × 10⁵ cells/well. After overnight incubation, a uniform scratch was made in the confluent monolayer using a 200-µL pipette tip. The wells were then washed three times with PBS to remove detached cells. Wound images were captured under a microscope immediately after scratching (0 h) and again at 24 h to assess wound closure. Transwell assay Cells in the logarithmic growth phase from each group were collected, resuspended in serum-free medium, and seeded into the upper chambers of Matrigel-coated Transwell inserts (BD Biosciences, Franklin Lakes, NJ, USA) at a density of 2 × 10⁴ cells/well. The lower chambers were filled with RPMI-1640 medium supplemented with 20% fetal bovine serum. After 24 h of incubation, non-invading cells on the upper surface of the membrane were gently removed with a cotton swab. Invading cells on the lower surface were fixed with 4% paraformaldehyde for 10 min, stained with 0.1% crystal violet, and observed under an Olympus microscope. Western blot Briefly, ESCC cells were harvested by trypsinization and washed three times with PBS. The cells were lysed in lysis buffer on ice for 20 min at 4 °C and centrifuged, and the supernatants were collected for subsequent analysis. For tissue protein extraction, 300 µL of lysis buffer was added to each sample, followed by thorough homogenization. The lysates were centrifuged at 12,000 rpm for 15 min at 4 °C, and the supernatants were collected. Protein concentrations were determined using a BCA assay. Equal amounts of protein (10 µg/lane) were separated by 10% SDS–PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes by electroblotting. The membranes were blocked with 5% non-fat dry milk for 2 h at room temperature and incubated overnight at 4 °C with the indicated primary antibodies. After three washes with TBST, the membranes were incubated with the corresponding secondary antibodies for 1 h at room temperature. Protein bands were visualized using enhanced chemiluminescence. Primary antibody dilutions were as follows: ASAP3, 1:1000; NEMO, 1:800; p65, 1:800; phospho-p65 (p-p65), 1:1000; cyclin B1, 1:5000; cyclin D1, 1:10000; and GAPDH, 1:10000. RT-qPCR Total RNA was extracted from cultured cells using FreeZol reagent (Vazyme, Nanjing, China) according to the manufacturer’s protocol. RNA (0.5 µg) was reverse-transcribed into cDNA using a PrimeScript RT-PCR Kit (Servicebio). Gene expression levels were quantified by real-time PCR using SYBR Premix Ex Taq and normalized to GAPDH. Relative mRNA expression was calculated using the 2^−ΔΔCt method. Primer sequences are listed in Table S1. Immunohistochemical (IHC) staining Paraffin-embedded sections from each group were deparaffinized and rehydrated as described above. After three washes with PBS, antigen retrieval was performed, followed by blocking with goat serum at room temperature for 30 min. The sections were then incubated overnight at 4 °C with primary antibodies against ASAP3 (1:100), p65 (1:100), phospho-p65 (p-p65; 1:100), and Ki-67 (1:100). The next day, sections were incubated with an HRP-labeled polymer at 37 °C for 60 min and developed with 3,3′-diaminobenzidine (DAB). After mounting with neutral resin, staining was examined under a light microscope. Xenograft mice model Paraffin-embedded sections from each group were deparaffinized and rehydrated as described above. After three washes with PBS, antigen retrieval was performed, and the sections were blocked with goat serum at room temperature for 30 min. The sections were then incubated overnight at 4 °C with primary antibodies against ASAP3 (1:100), p65 (1:100), phospho-p65 (p-p65; 1:100), and Ki-67 (1:100). The next day, the sections were incubated with an HRP-labeled polymer at 37 °C for 60 min and developed with 3,3′-diaminobenzidine (DAB). After mounting with neutral resin, staining was examined under a light microscope. Statistical analysis Statistical analyses were performed using GraphPad Prism 10.1.2 and SPSS 27. Data were tested for normality and homogeneity of variance. Continuous variables are expressed as the mean ± standard deviation (SD). Comparisons between two groups were performed using an independent-samples t test. Multiple-group comparisons were conducted using one-way analysis of variance (ANOVA) followed by Tukey’s multiple-comparisons test. For non-normally distributed data, the Kruskal–Wallis test was used. A P value < 0.05 was considered statistically significant. Results Upregulation of ASAP3 is associated with ESCC and poor outcome Immunohistochemistry was performed on 120 ESCC specimens. ASAP3, NEMO, phosphorylated p65 (p-p65), and MMP9 expression levels were significantly higher in ESCC tissues than in adjacent non-tumor tissues (Table 1). ASAP3, NEMO, and MMP9 were largely negative in adjacent tissues but strongly expressed in the cytoplasm of ESCC cells. Total p65 was mainly localized in the cytoplasm and showed relatively low expression in both tumor and adjacent tissues. In contrast, p-p65 was absent in adjacent tissues but showed strong nuclear staining in ESCC tissues (Fig. 1). Clinicopathological analysis showed that positive ASAP3 expression was associated with tumor size (P < 0.001), differentiation degree (P = 0.031), depth of invasion (P < 0.001), and pathological stage (P = 0.019). Positive NEMO expression was associated with tumor size (P = 0.007) and depth of invasion (P < 0.001). Positive p-p65 expression was associated with tumor size (P = 0.002), differentiation degree (P < 0.001), depth of invasion (P = 0.002), and lymph node metastasis (P = 0.007). Positive MMP9 expression was associated with tumor size (P < 0.001), differentiation degree, and depth of invasion (P < 0.001) (Table 2). Spearman correlation analysis was then performed to examine the relationships among these proteins in ESCC tissues. ASAP3 expression was positively correlated with NEMO expression (r = 0.396, P < 0.001), with co-positivity observed in 101 cases (Supplementary Fig. S2). ASAP3 expression was also positively correlated with p-p65 expression (r = 0.368, P < 0.001), with co-positivity observed in 98 cases. In addition, ASAP3 expression was positively correlated with MMP9 expression (r = 0.613, P = 0.003), with co-positivity observed in 103 cases. Collectively, these findings suggest that ASAP3 may contribute to ESCC progression. Table 1Expression of ASAP3, NEMO, P-P65, and MMP9in ESCC and adjacent tissuesNamePathological parameters/ N(%)χ2 valueP valueESCC tissuePara cancerous tissueASAP3Positive103 (85.8)23 (19.2)106.934< 0.001Negative17 (14.2)97 (80.8)NEMOPositive110 (91.7)29 (24.2)112.162< 0.001Negative10 (8.3)91 (75.8)P-P65Positive109 (90.8)17 (14.2)141.420< 0.001Negative11 (9.2)103 (85.8)MMP9Positive113 (94.2)16 (13.3)157.704< 0.001Negative7 (5.8)104 (86.7)P<0.05, the difference was statistically significant Table 1Expression of ASAP3, NEMO, P-P65, and MMP9in ESCC and adjacent tissuesNamePathological parameters/ N(%)χ2 valueP valueESCC tissuePara cancerous tissueASAP3Positive103 (85.8)23 (19.2)106.934< 0.001Negative17 (14.2)97 (80.8)NEMOPositive110 (91.7)29 (24.2)112.162< 0.001Negative10 (8.3)91 (75.8)P-P65Positive109 (90.8)17 (14.2)141.420< 0.001Negative11 (9.2)103 (85.8)MMP9Positive113 (94.2)16 (13.3)157.704< 0.001Negative7 (5.8)104 (86.7)P<0.05, the difference was statistically significant Expression of ASAP3, NEMO, P-P65, and MMP9in ESCC and adjacent tissues P<0.05, the difference was statistically significant Table 2Relationship between expression of ASAP3, NEMO, P-P5 and MMP9 in ESCC and clinicopathological parametersClinicopathologicalparameters N ASAP3expression P NEMOexpression P P-P65expression P MMP9expression P 120negativepositivenegativepositivenegativepositivenegativepositiveGender Female333300.3951320.2813431.0002311.000 Male871473978897582Age < 655910490.441640.5268510.1235540.268 ≥ 65617545357358259Tumor size <3331419< 0.0017260.0078250.0026270.002 ≥ 387384384384186Degree of differentiation Well differentiated173150.0311160.948512< 0.001117< 0.001 Moderatelydifferentiated871473879582681 Poorly differentiated15015114015015Depth of invasion Mucosa642< 0.00133< 0.001330.00233< 0.001 Muscularis47938443344344 Full-thickness67463364562166pTNM stage IB319220.0195260.1706250.0674270.141 IIA, B84876579579381 IIIA, B,C505050505Lymph node metastasis No7713640.2908690.27511660.0075721 Yes43439241043241P<0.05, the difference was statistically significant Table 2Relationship between expression of ASAP3, NEMO, P-P5 and MMP9 in ESCC and clinicopathological parametersClinicopathologicalparameters N ASAP3expression P NEMOexpression P P-P65expression P MMP9expression P 120negativepositivenegativepositivenegativepositivenegativepositiveGender Female333300.3951320.2813431.0002311.000 Male871473978897582Age < 655910490.441640.5268510.1235540.268 ≥ 65617545357358259Tumor size <3331419< 0.0017260.0078250.0026270.002 ≥ 387384384384186Degree of differentiation Well differentiated173150.0311160.948512< 0.001117< 0.001 Moderatelydifferentiated871473879582681 Poorly differentiated15015114015015Depth of invasion Mucosa642< 0.00133< 0.001330.00233< 0.001 Muscularis47938443344344 Full-thickness67463364562166pTNM stage IB319220.0195260.1706250.0674270.141 IIA, B84876579579381 IIIA, B,C505050505Lymph node metastasis No7713640.2908690.27511660.0075721 Yes43439241043241P<0.05, the difference was statistically significant Relationship between expression of ASAP3, NEMO, P-P5 and MMP9 in ESCC and clinicopathological parameters Moderately differentiated P<0.05, the difference was statistically significant ASAP3 is Upregulated in ESCC Cell Lines Based on the elevated ASAP3 expression in clinical ESCC specimens, we next investigated its function in vitro. ASAP3 protein levels were assessed by Western blotting in three ESCC cell lines: KYSE30, KYSE150, and KYSE450. KYSE450 cells exhibited the highest ASAP3 expression and were therefore selected for lentiviral transduction (Fig. 2A, B), (P<0.05). To establish stable ASAP3 knockdown, three ASAP3-targeting shRNAs were tested. Knockdown efficiency was evaluated by Western blotting, and shASAP3#3 showed the strongest silencing effect. Therefore, shASAP3#3 was used in all subsequent assays (Fig. 2C, D). The differences were statistically significant (P < 0.05). Fig. 1Immunohistochemical findings of para-cancerous tissue and ESCC tissue in clinical paraffin-embedded specimens. Immunohistochemical results for ASAP3, NEMO, p-p65, and MMP9 in para-cancerous tissue and ESCC tissue Immunohistochemical findings of para-cancerous tissue and ESCC tissue in clinical paraffin-embedded specimens. Immunohistochemical results for ASAP3, NEMO, p-p65, and MMP9 in para-cancerous tissue and ESCC tissue Fig. 2ASAP3 is upregulated in ESCC cell lines. A Western blotting showing ASAP3 expression in three esophageal squamous cell carcinoma cell lines; B Quantitative Chart for Chart A; C Detection of ASAP3 Transfection Efficiency by Western Blot; D Quantitative Chart for Chart C. This figure shows the mean ± standard deviation of statistical results from three independent experiments; *P < 0.05, ***P < 0.001 ASAP3 is upregulated in ESCC cell lines. A Western blotting showing ASAP3 expression in three esophageal squamous cell carcinoma cell lines; B Quantitative Chart for Chart A; C Detection of ASAP3 Transfection Efficiency by Western Blot; D Quantitative Chart for Chart C. This figure shows the mean ± standard deviation of statistical results from three independent experiments; *P < 0.05, ***P < 0.001 ASAP3 promotes proliferation of ESCC cells in vivo To assess the effect of ASAP3 on ESCC cell proliferation, we performed CCK-8 and colony formation assays. The CCK-8 assay showed that shASAP3#3 cells had significantly lower proliferative capacity than KYSE450 (CON) and NC cells (Fig. 3A). Similarly, the colony formation assay showed markedly reduced clonogenic ability in the shASAP3#3 group compared with the CON group (Fig. 3B, C), with statistically significant differences (P < 0.05).To explore the underlying mechanism, apoptosis was assessed by flow cytometry. The apoptotic rate was significantly higher in the shASAP3#3 group than in the CON group (Fig. 3D, E). Western blot analysis further showed that cyclin B1 and cyclin D1 expression levels were significantly decreased in shASAP3#3 cells compared with the CON and NC groups (P < 0.05; Fig. 3F, G). Together, these findings suggest that ASAP3 knockdown suppresses ESCC cell proliferation, at least in part by promoting apoptosis and downregulating cell cycle–related proteins. Fig. 3ASAP3 knockdown inhibits tumor proliferation in ESCC cells in vitro. A CCK-8 assay was used to detect cell proliferation. B, C Plate cloning experiment. D, E Apoptosis was detected by flow cytometry. F, G Western blotting showing the expression of CyclinB1, CyclinD1.This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, *** P < 0.001, ****P < 0.0001 ASAP3 knockdown inhibits tumor proliferation in ESCC cells in vitro. A CCK-8 assay was used to detect cell proliferation. B, C Plate cloning experiment. D, E Apoptosis was detected by flow cytometry. F, G Western blotting showing the expression of CyclinB1, CyclinD1.This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, *** P < 0.001, ****P < 0.0001 ASAP3 promotes migration and invasion of ESCC in vivo To determine whether ASAP3 regulates ESCC cell migration and invasion, wound-healing and Transwell assays were performed. In the wound-healing assay, wound closure did not differ significantly between the CON and NC groups. However, the shASAP3#3 group showed a larger residual wound area than the CON group, indicating reduced migratory capacity after ASAP3 silencing (Fig. 4A, B). Cell invasion was further assessed using a Transwell assay. The number of invading cells was markedly lower in the shASAP3#3 group than in the CON and NC groups, indicating significantly reduced invasive ability after ASAP3 knockdown (P < 0.05; Fig. 4C, D). MMP9 expression was then examined by Western blotting and RT-qPCR. ASAP3 knockdown significantly decreased MMP9 protein and mRNA expression in ESCC cells (P < 0.05; Fig. 4E, G). Taken together, these results suggest that ASAP3 downregulation suppresses the proliferation, migration, and invasion of KYSE450 ESCC cells, supporting the role of ASAP3 in ESCC cell motility and invasiveness. Fig. 4ASAP3 knockdown inhibits tumor migration and invasion in ESCC cells in vitro. A, B Scratch healing test, scale bar 200 μm. C, D Transwell was used to detect cell invasion, scale bar 100 μm (E) Western blot showing the expression of MMP9 (F Quantitative Chart of E (G) RT-qPCR showing the expression of the MMP9. This figure shows the mean ± standard deviation of statistical results from three independent experiments, * P < 0.05, ** P < 0.01, *** P < 0.001 ASAP3 knockdown inhibits tumor migration and invasion in ESCC cells in vitro. A, B Scratch healing test, scale bar 200 μm. C, D Transwell was used to detect cell invasion, scale bar 100 μm (E) Western blot showing the expression of MMP9 (F Quantitative Chart of E (G) RT-qPCR showing the expression of the MMP9. This figure shows the mean ± standard deviation of statistical results from three independent experiments, * P < 0.05, ** P < 0.01, *** P < 0.001 ASAP3 regulates the malignant progression of ESCC through the NF - κB signaling pathway in vivo Previous studies have shown that NEMO is an essential activator of the canonical NF-κB pathway, and that NF-κB plays a critical role in regulating the proliferation and apoptosis of various cancer cells [20, 21]. Therefore, we sought to investigate the mechanism by which ASAP3 promotes esophageal cancer progression through activation of the NF-κB signaling pathway. First, we performed structural prediction using AlphaFold3, followed by visualization of ASAP3 and NEMO using PyMOL. The results showed potential interaction sites between ASAP3 and NEMO (Fig. 5A). Next, immunofluorescence staining was performed to examine whether ASAP3 and NEMO colocalize in esophageal cancer cells. The results demonstrated that ASAP3 and NEMO were colocalized in the cytoplasm of KYSE450 cells (Fig. 5B). To further confirm the direct interaction between ASAP3 and NEMO, we performed immunoprecipitation using an ASAP3-specific antibody to pull down its protein-binding partners, followed by detection of the immunoprecipitated products with a NEMO antibody. Endogenous co-immunoprecipitation assays showed that endogenous ASAP3 and NEMO formed a protein complex in esophageal cancer cells. Correspondingly, ASAP3 was also detected in endogenous NEMO immunoprecipitates, further suggesting an interaction between ASAP3 and NEMO (Fig. 5C, D). We then examined the protein expression levels of NEMO, p65, and phosphorylated p65 (p-p65) by Western blotting. The results showed that NEMO protein expression was increased, and the p-p65/p65 ratio was significantly elevated (P < 0.05) (Fig. 5E, F). In addition, NEMO mRNA levels were evaluated by RT-qPCR, and the results showed that NEMO mRNA expression was consistent with its protein expression level (P < 0.05) (Fig. 5G). Together, these findings suggest that ASAP3 may promote NEMO expression during ESCC progression, thereby activating the NF-κB signaling pathway. ASAP3 may enhance NEMO-mediated activation of NF-κB signaling, ultimately promoting the proliferation, migration, and invasion of ESCC cells. Fig. 5ASAP3 regulates NFκB signaling pathways in ESCC. A The protein interaction model of ASAP3 and NEMO was predicted using AlphaFold3 and visualized using PyMOL. B Immunofluorescence staining was performed to examine the localization of ASAP3 and NEMO in KYSE450 cells. C, D Endogenous forward and reverse co-immunoprecipitation assays were performed to verify the interaction between ASAP3 and NEMO. E, F Western blotting showing the expression of NEMO, P65, P-P65protein. G RT-qPCR showing the expression of the NEMO mRNA. This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, ** P < 0.01 ASAP3 regulates NFκB signaling pathways in ESCC. A The protein interaction model of ASAP3 and NEMO was predicted using AlphaFold3 and visualized using PyMOL. B Immunofluorescence staining was performed to examine the localization of ASAP3 and NEMO in KYSE450 cells. C, D Endogenous forward and reverse co-immunoprecipitation assays were performed to verify the interaction between ASAP3 and NEMO. E, F Western blotting showing the expression of NEMO, P65, P-P65protein. G RT-qPCR showing the expression of the NEMO mRNA. This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, ** P < 0.01 Silencing ASAP3 can inhibit the in vivo growth of esophageal cancer Our in vitro results showed that ASAP3 downregulation suppresses ESCC cell progression; however, whether this effect occurs in vivo remained unclear. Therefore, CON, NC, and shASAP3#3 cells were injected into the axillary region of nude mice to establish xenograft models and evaluate the in vivo role of ASAP3. As shown in Fig. 6A, excised tumors provided direct evidence that ASAP3 silencing reduced tumorigenic capacity. Consistently, ASAP3 knockdown inhibited tumor growth, as reflected by reduced tumor volume and weight (Fig. 6B, C).Because clinical specimens showed increased ASAP3, NEMO, and phosphorylated p65 (p-p65) expression in ESCC, we further performed immunohistochemistry on xenograft tumors. The results showed upregulated ASAP3, NEMO, and p-p65 expression in the xenograft model (Fig. 6D). To further validate the association between ASAP3 and NF-κB signaling in vivo, Western blotting was performed to assess the expression of ASAP3, NEMO, p65, p-p65, MMP9, cyclin B1, and cyclin D1. Compared with the CON group, the shASAP3#3 group showed decreased protein levels of ASAP3, NEMO, MMP9, cyclin B1, and cyclin D1, along with reduced p65 phosphorylation. In summary, ASAP3 silencing reduces NEMO expression and p65 phosphorylation, thereby inhibiting ESCC tumor growth (Fig. 7). Fig. 6Effects of ASAP3 knockdown in vivo tumor growth. A Nude mouse tumor-bearing photo B, C The turmor growth curve and tumor weight in nude mice after being injected with KYSE450 cells expressing NC or shASAP3#3. D Immunohistochemistry results of ASAP3, p65, p-p65, Ki-67 in tumor, scale bar 200 μm. E, F Western blot assays assessed ASAP3, NEMO, P65, P-P65, MMP9, CyclinB1, CyclinD1. This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, ***P < 0.001 Effects of ASAP3 knockdown in vivo tumor growth. A Nude mouse tumor-bearing photo B, C The turmor growth curve and tumor weight in nude mice after being injected with KYSE450 cells expressing NC or shASAP3#3. D Immunohistochemistry results of ASAP3, p65, p-p65, Ki-67 in tumor, scale bar 200 μm. E, F Western blot assays assessed ASAP3, NEMO, P65, P-P65, MMP9, CyclinB1, CyclinD1. This figure shows the mean ± standard deviation of statistical results from three independent experiments; * P < 0.05, ***P < 0.001 Discussion Esophageal squamous cell carcinoma (ESCC) is a common malignancy. Despite advances in clinical diagnosis and treatment, ESCC morbidity and mortality remain high in many countries, particularly in China [22, 23]. Therefore, further clinical studies are urgently needed to validate specific biomarkers for ESCC screening, early diagnosis, and prognostic prediction and to develop new therapeutic strategies for patients with ESCC. Increasing evidence indicates that ASAP3 acts as an oncogene in several human cancers and contributes to tumor initiation and progression. As a member of the ArfGAP family, ASAP3 may be involved in tumor cell migration and invasion [24]. Tian et al. [10] reported that ASAP3 is upregulated in colorectal cancer, promotes malignant progression, and predicts poor patient survival [25]. Zhang et al. [8]found that ASAP3 overexpression enhances the migration and invasion of human lung adenocarcinoma cells and accelerates tumor progression. Fan et al. [9] also showed that elevated ASAP3 expression is associated with poor clinical outcomes in non-small cell lung cancer. In addition, Su et al. [12] reported that increased ASAP3 expression is correlated with glioma prognosis, consistent with previous findings. Beyond its association with clinical prognosis, ASAP3 may contribute to esophageal cancer progression through multiple mechanisms. Tumor invasion and metastasis are closely related to extracellular matrix remodeling, in which matrix metalloproteinases, including MMP9, play important roles [26]. In the present study, we found that MMP9 expression was increased in ESCC, which may promote ESCC cell migration and invasion. NF-κB is a multifunctional factor involved in various physiological and pathological processes, including development, immunity, tissue homeostasis, and inflammation [15].At the molecular and cellular levels, NF-κB regulates gene expression, apoptosis, and cell proliferation. Its aberrant activation in tumor cells promotes survival and proliferation [27]. Feng et al. [28] reported that NCAPG knockdown suppresses the proliferation of bladder cancer cells via the NF-κB signaling pathway. NEMO is indispensable for activation of the canonical NF-κB pathway. Its N-terminus contains an IKK-binding domain (IBD), which interacts with the NEMO-binding domain (NBD) of IKK [29]. Its C-terminus interacts with upstream signaling molecules, such as RIP, thereby promoting NEMO oligomerization and phosphorylation and enabling TNF-α- and interleukin-1 (IL-1)-mediated activation of NF-κB signaling [30–32]. Studies have shown that Rad50 promotes the aggressiveness of high-grade serous ovarian cancer by activating the NF-κB pathway [33]. Lioba et al. [17] found that, in an SCLC mouse model driven by combined loss of RB1 and TP53, deletion of NEMO and consequent inhibition of the canonical NF-κB pathway significantly delayed tumor initiation, slowed tumor growth, and prolonged mouse survival, indicating that canonical NEMO activation plays an important tumor-promoting role in NF-κB signaling during SCLC development and progression. In our study, we first analyzed 120 clinical tissue specimens and found increased NEMO expression and elevated p65 phosphorylation, which in turn activated the NF-κB signaling pathway. Second, in vitro experiments showed that silencing ASAP3 reduced NEMO expression and inhibited NF-κB activation, thereby suppressing the malignant progression of ESCC. Finally, our in vivo experiments demonstrated that downregulation of ASAP3 slowed tumor growth and reduced tumor volume. Clinicopathological analysis showed that ASAP3 expression was higher in ESCC tissues than in corresponding adjacent tissues and was associated with tumor size, depth of invasion, and pathological stage, suggesting that ASAP3 may contribute to ESCC progression. To determine the role of ASAP3 in ESCC, we used lentiviral transduction to knock down ASAP3 expression in KYSE450 cells. ASAP3 silencing attenuated ESCC cell proliferation, migration, and invasion. These findings are consistent with previous studies showing that elevated ASAP3 expression is associated with poor clinical prognosis in non-small cell lung cancer, hepatocellular carcinoma, adult glioma, and colorectal cancer. Together, these results suggest that ASAP3 may play an oncogenic role in ESCC. In vivo, xenograft models established using CON, NC, and shASAP3#3 cells showed reduced tumor weight and volume in ASAP3-silenced tumors compared with the CON group. Similarly, Tian et al. reported decreased tumor volume and weight after ASAP3 silencing in colorectal cancer models, which is consistent with our findings. The molecular mechanism by which ASAP3 promotes ESCC cell proliferation, invasion and migration remains unclear. We found in the literature that ASAP3 is closely related to the NFκB signaling pathway, while ASAP3 interacts with NEMO and thus activates NF-κBand that the NF-κB signaling pathway is considered to be one of the classical signaling pathways in the development and progression of most human diseases, including malignant tumors. Signaling pathways have many other functions, such as inflammation, tumors and immune diseases [34–36]. The NF-κB signaling pathway is involved in inflammation, tumorigenesis, and immune regulation and is frequently activated in tumors. Previous studies have shown that ASAP3 promotes p65 nuclear translocation in colon cancer. Similarly, our study found that ASAP3 may promote p65 nuclear translocation in ESCC [10]. However, this study has several limitations. The precise mechanism by which ASAP3 promotes p65 nuclear translocation has not been fully elucidated. In addition, the regulatory relationship between ASAP3 and MMP9 requires further investigation. Therefore, more comprehensive studies are needed to clarify the molecular mechanisms by which ASAP3 contributes to ESCC progression. Conclusion In conclusion, ASAP3 is highly expressed in ESCC and is associated with poor prognosis. ASAP3 knockdown suppresses ESCC cell proliferation, migration, invasion, and tumor growth, possibly in part by inhibiting NEMO-mediated NF-κB signaling. NF-κB signaling is described as a potential mechanism by which ASAP3 may promote ESCC progression, rather than the exclusive pathway. These findings suggest that ASAP3 may serve as a potential prognostic biomarker and therapeutic target for ESCC (Fig. 7). Fig. 7ASAP3 is upregulated in esophageal cancer tissues, which increases Nemo expression, thereby promoting p65 phosphorylation and ultimately enhancing the proliferation, migration, and invasion of ESCC ASAP3 is upregulated in esophageal cancer tissues, which increases Nemo expression, thereby promoting p65 phosphorylation and ultimately enhancing the proliferation, migration, and invasion of ESCC Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3.